Evercore ISI upgraded Edwards Lifesciences (EW) to Outperform from In Line with a price target of $88, up from $80. Competitive fears have abated and the firm sees a potential inflection in TAVR procedures, driven by asymptomatic TAVR, the analyst tells investors. The firm identifies the moderate AS trial readout as another potential positive catalyst.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target lowered to $85 from $95 at Stifel
- Edwards Lifesciences management to meet with Piper Sandler
- Edwards Lifesciences: Strategic Positioning and Growth Potential Drive Buy Rating Amid TAVR Market Expansion
- Edwards Lifesciences Enters Accelerated Share Repurchase Agreement
- Edwards Lifesciences announces $500M accelerated share repurchase